RVMD ▲ +1.0% - Revolution Medicines, Inc.
$RVMD RevMed Rated New Buy at Morgan Stanley on Oncology Drug Upside, PT $255
Revolution Medicines rose 1.0% after Morgan Stanley initiated coverage with a Buy rating and a $255 price target, citing upside potential from the company's oncology drug pipeline. The new positive analyst coverage and price target above current levels provided support for the intraday gain.
10-SEP-2026 07:41 AM ET
Share this post
More filings for $RVMD
RVMD ▼ -0.3% - Revolution Medicines, Inc.Sep 2, 2026RVMD ▲ +0.4% - Revolution Medicines, Inc.Aug 31, 2026RVMD ▲ +3.3% - Revolution Medicines, Inc.Aug 27, 2026RVMD - Revolution Medicines, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026RVMD - Revolution Medicines, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026$RVMD SEC Filing Update (29-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 29, 2026
View full $RVMD filing history →💬 Comments
Loading comments…
Leave a comment